The <scp>BCL</scp>2 antagonist <scp>ABT</scp>‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <i><scp>CXCR</scp>4</i><sup><i>Wild‐type</i></sup> and <i><scp>CXCR</scp>4</i><scp><sup><i>WHIM</i></sup></scp> mutated Waldenstrom macroglobulinaemia cellsYang Cao, Steven P. Treon, Guang Yang et al.|British Journal of Haematology|2015Cited by 71
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A. Graf, Ajay K. Gopal, Qian Wu et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 13